WallStSmart

Medirom Healthcare Technologies Inc (MRM)vsRollins Inc (ROL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medirom Healthcare Technologies Inc generates 110% more annual revenue ($8.07B vs $3.84B). ROL leads profitability with a 13.8% profit margin vs 0.5%. MRM trades at a lower P/E of 3.0x. ROL earns a higher WallStSmart Score of 52/100 (C-).

MRM

Hold

39

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 8.3Quality: 4.0
Piotroski: 3/9Altman Z: 0.93

ROL

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 8.5Value: 5.3Quality: 5.0
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRMUndervalued (+62.4%)

Margin of Safety

+62.4%

Fair Value

$3.46

Current Price

$1.13

$2.33 discount

UndervaluedFair: $3.46Overvalued
ROLUndervalued (+30.2%)

Margin of Safety

+30.2%

Fair Value

$67.65

Current Price

$46.51

$21.14 discount

UndervaluedFair: $67.65Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRM3 strengths · Avg: 9.3/10
P/E RatioValuation
3.0x10/10

Attractively priced relative to earnings

Return on EquityProfitability
63.9%10/10

Every $100 of equity generates 64 in profit

EPS GrowthGrowth
27.8%8/10

Earnings expanding 27.8% YoY

ROL1 strengths · Avg: 10.0/10
Return on EquityProfitability
38.3%10/10

Every $100 of equity generates 38 in profit

Areas to Watch

MRM4 concerns · Avg: 3.0/10
Market CapQuality
$8.93M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.5%3/10

0.5% margin — thin

Debt/EquityHealth
1.753/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ROL4 concerns · Avg: 3.3/10
Price/BookValuation
16.3x4/10

Trading at 16.3x book value

EPS GrowthGrowth
1.3%4/10

1.3% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.402/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : MRM

The strongest argument for MRM centers on P/E Ratio, Return on Equity, EPS Growth.

Bull Case : ROL

The strongest argument for ROL centers on Return on Equity. Revenue growth of 10.2% demonstrates continued momentum.

Bear Case : MRM

The primary concerns for MRM are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.75 is elevated, increasing financial risk. Thin 0.5% margins leave little buffer for downturns.

Bear Case : ROL

The primary concerns for ROL are Price/Book, EPS Growth, Piotroski F-Score. A P/E of 43.3x leaves little room for execution misses.

Key Dynamics to Monitor

MRM carries more volatility with a beta of 1.00 — expect wider price swings.

ROL is growing revenue faster at 10.2% — sustainability is the question.

ROL generates stronger free cash flow (111M), providing more financial flexibility.

Monitor PERSONAL SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ROL scores higher overall (52/100 vs 39/100) and 10.2% revenue growth. MRM offers better value entry with a 62.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medirom Healthcare Technologies Inc

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

MEDIROM Healthcare Technologies Inc. provides comprehensive healthcare services in Japan. The company is headquartered in Tokyo, Japan.

Visit Website →

Rollins Inc

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Rollins, Inc. is a North American consumer and commercial services company.

Visit Website →

Want to dig deeper into these stocks?